Kahn Swick & Foti, LLC has notified investors in ADMA Biologics, Inc. of an August 10, 2026 deadline to apply for lead plaintiff in a securities class action lawsuit. The lawsuit, pending in the United States District Court for the District of New Jersey, seeks to recover losses for investors who purchased ADMA securities between August 9, 2024 and March 25, 2026. The complaint alleges that the company and certain executives failed to disclose material information, including an undisclosed related party transaction, channel stuffing to inflate revenue, and inadequate internal controls. Investors who suffered losses during the class period may contact KSF Managing Partner Lewis Kahn to learn more about the case, which is captioned Mazzarino v. ADMA Biologics, Inc., et al, No. 26-cv-04793.
ADMA Biologics IncSecurities class action alleges undisclosed related party transaction, channel stuffing, and inadequate internal controls.
